| 1. |
Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci, 2014, 55(3): 1735-1748.
|
| 2. |
Bahn RS. Graves’ ophthalmopathy. N Engl J Med, 2010, 362(8): 726-738.
|
| 3. |
Bartalena L, Piantanida E, Gallo D, et al. Epidemiology, natural history, risk factors, and prevention of Graves’ orbitopathy. Front Endocrinol (Lausanne), 2020, 11: 615993.
|
| 4. |
Muralidhar A, Das S, Tiple S. Clinical profile of thyroid eye disease and factors predictive of disease severity. Indian J Ophthalmol, 2020, 68(8): 1629-1634.
|
| 5. |
Tramunt B, Imbert P, Grunenwald S, et al. Sight-threatening Graves’ orbitopathy: twenty years’ experience of a multidisciplinary thyroid-eye outpatient clinic. Clin Endocrinol (Oxf), 2019, 90(1): 208-213.
|
| 6. |
Du B, Wang Y, Yang M, et al. Clinical features and clinical course of thyroid-associated ophthalmopathy: a case series of 3620 Chinese cases. Eye (Lond), 2021, 35(8): 2294-2301.
|
| 7. |
Rivera-Grana E, Lin P, Suhler EB, et al. Methotrexate as a corticosteroid-sparing agent for thyroid eye disease. J Clin Exp Ophthalmol. 2015, 6(2): 422.
|
| 8. |
Men CJ, Kossler AL, Wester ST. Updates on the understanding and management of thyroid eye disease. Ther Adv Ophthalmol. 2021, 13: 25158414211027760.
|
| 9. |
Mourits MP, Prummel MF, Wiersinga WM, et al. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf), 1997, 47(1): 9-14.
|
| 10. |
Werner SC. Modification of the classification of the eye changes of Graves’ disease. Am J Ophthalmol, 1977, 83(5): 725-727.
|
| 11. |
Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol, 2021, 185(4): G43-G67.
|
| 12. |
Li YJ, Luo Y, Xie XQ, et al. The efficacy of intensity modulated radiation therapy in treating thyroid-associated ophthalmopathy and predictive factors for treatment response. Sci Rep, 2017, 7(1): 17533.
|
| 13. |
李冬梅, 姜雪. 规范甲状腺相关眼病眶周注射糖皮质激素的治疗. 中华眼科杂志, 2022, 58(9): 641-645.
|
| 14. |
Li YJ, Luo Y, He WM, et al. Clinical outcomes of graves’ ophthalmopathy treated with intensity modulated radiation therapy. Radiat Oncol, 2017, 12(1): 171.
|
| 15. |
Mikoś H, Mikoś M, Obara-Moszyńska M, et al. The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD). Endokrynol Pol, 2014, 65(2): 150-155.
|
| 16. |
樊琳琳, 吴君丽, 卢颖, 等. 激素冲击治疗联合放疗对中重度 Graves 眼病临床疗效分析. 现代生物医学进展, 2016, 16(24): 4734-4736, 4743.
|
